# Pharma Buyers Shift Biologics Sourcing

Samsung Biologics disclosed on November 3, 2026, a five-year biologics manufacturing agreement worth **$323 million** with an unnamed global pharmaceutical company; the filing linked the client’s sourcing decision to the U.S. Biosecure Act. The agreement is a private-sector deal, not a U.S. government award, but it shows federal procurement restrictions influencing commercial CDMO sourcing. OMB is expected to publish a Biotechnology Companies of Concern list by December 2026, which could further affect supplier choices for organizations with federal contract or grant exposure.

- Companies with federal contracts or grants should assess dependencies on potentially affected biologics suppliers and begin qualifying alternatives; manufacturing transfers typically take 12–24 months.
- Samsung Biologics was identified as the agreement’s awardee. WuXi AppTec and WuXi Biologics are referenced as potential incumbent suppliers in the Biosecure Act context, and Lotte Biologics as an alternative CDMO.
- A separate extracted signal records an approximately $22.6 million expansion of an existing U.S. pharmaceutical manufacturing contract, indicating additional sourcing activity; its exact disclosure date was not provided.

**Jurisdictions:** federal
**Industries:** Healthcare
**Topics:** Regulatory Compliance, Policy
**Published:** November 04, 2026

### Government Entities
- Office of Management and Budget (OMB)
- U.S. Department of Defense (DoD)
- U.S. Food and Drug Administration (FDA)
- National Institutes of Health (NIH)
- U.S. Department of Commerce (Commerce Department)

### Vendors
- Samsung Biologics (CDMO awardee)
- WuXi AppTec (Potential incumbent supplier referenced in Biosecure Act compliance context)
- WuXi Biologics (Potential incumbent CDMO referenced in Biosecure Act compliance context)
- Lotte Biologics (Alternative CDMO)

### Sources
- [Samsung Biologics Logs $323M Contract as Biosecure Act Redirection Enters Procurement Data](https://www.techtimes.com/articles/329999/20261103/samsung-biologics-logs-323m-contract-biosecure-act-redirection-enters-procurement-data.htm) - Tech Times